The Center for Biosimilars® recaps the top stories for the week of January 27, 2020.
Hi, I’m Matthew Gavidia for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of January 27, 2020.
Number 5: Health New England, a nonprofit health plan in Massachusetts, says it achieved 93% utilization of biosimilar infliximab by requiring prior authorization of the brand product, Remicade.
Number 4: An industry executive with Boehringer Ingelheim discusses the impact that the international pricing index could have on drug development.
Number 3: Developing trust in a biosimilar and working out a long-range, multipronged marketing strategy is key to a successful launch, industry executives say.
Number 2: Panelists at the Specialty Therapies and Biosimilars Conference review how successive patents can be filed to keep an original product in a position of market dominance.
Number 1: Pfizer says its 3 oncology biosimilar products—bevacizumab, rituximab, and trastuzumab—will have the lowest wholesale acquisition cost among all other oncology biosimilars.
To read all of these articles and more, visit centerforbiosimilars.com.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Annual STADA Report Shows Record Profit Growth for 2023
March 25th 2024Germany-based biosimilar manufacturer STADA Arzneimittel reports strong financial performance in 2023 with double digit sales growth and billions in profits. The CEO credits the company’s success on their strong company culture and focus for innovation.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.